National Center for Advancing Translational Sciences (NCATS)

Scientific Director: Anton Simeonov, Ph.D.

Intramural researchers in the NCATS Division of Preclinical Innovation (DPI) lead scientific programs and projects designed to advance new technologies that make the preclinical phase and early clinical phases of translation more predictive and efficient. They also work to “de-risk” novel targets and disease projects to make them more attractive for commercial investment so that new treatments can reach patients faster.

NCATS’ intramural research most often is conducted in collaboration with other NIH intramural investigators as well as academic, nonprofit and industry investigators by providing molecules, a variety of agreements and mechanisms, and other tools and resources. Researchers also work to license potential therapeutics developed by NCATS and its collaborators that have shown promise in early-stage clinical trials to biopharmaceutical companies to support additional clinical trials required for regulatory approval.

The NCATS DPI includes its NIH Chemical Genomics Center, which was created as a Comprehensive Screening Center in the Molecular Libraries Probe Production Centers Network, is part of the NIH Common Fund Molecular Libraries Program. The goals of this program are to translate the discoveries of the Human Genome Project into biological and disease insights and ultimately new therapeutics for human disease through small molecule assay development, high-throughput screening, cheminformatics and chemistry.

Additional NCATS’ DPI programs, many of which support NIH intramural research, include:

  • Assay Development and High-Throughput Screening
  • Bridging Interventional Development Gaps (BrIDGs)
  • Chemistry Technology
  • RNA interference
  • Therapeutics for Rare and Neglected Diseases (TRND)
  • Toxicology in the 21st Century (Tox21)

Learn more about the National Center for Translational Sciences’ Division of Preclinical Innovation.